Werewolf Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $18.6M
- Price
- $0.4093
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.02%
- Volume
- 155.6K
About
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Quick stats
Shares outstanding48.6M
Computed float36.2M
Float / shares74.4%
Cash runway (months)6.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001785530
Websitehttps://werewolftx.com
AI Summary
AI-generated1/4
standardneutralearnings
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics reported Q2 2026 revenue of $21.0 million, derived entirely from the sale of its JZP898 program to Jazz Pharmaceuticals, resulting in net income of $3.7 million compared to a year-ago loss.
The company has initiated a strategic alternatives review with Piper Sandler and significantly reduced R&D spending by over 50% year-over-year to conserve capital, which currently totals $22.0 million with an expected runway into Q2 2027.
Management plans to provide updates on the strategic review process and clinical data readouts for WTX-124 and WTX-330 in the second half of the year.
Red flags
- Cash runway extends only to Q2 2027
- Strategic alternatives review initiated indicating potential sale or restructuring
- R&D expenses cut by >50% YoY ($13.1M to $6.2M), signaling pipeline contraction
- Revenue driven solely by one-time asset sale with zero collaboration revenue in prior year